- Home
- ELVN vs GDEN Comparison
ELVN vs GDEN Comparison
Compare ELVN & GDEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- GDEN
- Stock Information
- Founded
- ELVN 2016
- GDEN 1998
- Country
- ELVN United States
- GDEN United States
- Employees
- ELVN N/A
- GDEN N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- GDEN Services-Misc. Amusement & Recreation
- Sector
- ELVN Health Care
- GDEN Consumer Discretionary
- Exchange
- ELVN Nasdaq
- GDEN Nasdaq
- Market Cap
- ELVN 1.1B
- GDEN 938.2M
- IPO Year
- ELVN 2020
- GDEN 1999
- Fundamental
- Price
- ELVN $27.53
- GDEN $31.19
- Analyst Decision
- ELVN Strong Buy
- GDEN Strong Buy
- Analyst Count
- ELVN 3
- GDEN 5
- Target Price
- ELVN $34.33
- GDEN $37.80
- AVG Volume (30 Days)
- ELVN 309.7K
- GDEN 223.9K
- Earning Date
- ELVN 11-07-2024
- GDEN 10-31-2024
- Dividend Yield
- ELVN N/A
- GDEN 3.20%
- EPS Growth
- ELVN N/A
- GDEN 468.13
- EPS
- ELVN N/A
- GDEN 8.97
- Revenue
- ELVN N/A
- GDEN $829,798,000.00
- Revenue This Year
- ELVN N/A
- GDEN N/A
- Revenue Next Year
- ELVN N/A
- GDEN $2.12
- P/E Ratio
- ELVN N/A
- GDEN $3.41
- Revenue Growth
- ELVN N/A
- GDEN N/A
- 52 Week Low
- ELVN $9.80
- GDEN $27.42
- 52 Week High
- ELVN $27.67
- GDEN $42.14
- Technical
- Relative Strength Index (RSI)
- ELVN 73.14
- GDEN 47.77
- Support Level
- ELVN $24.60
- GDEN $30.45
- Resistance Level
- ELVN $27.55
- GDEN $31.81
- Average True Range (ATR)
- ELVN 1.41
- GDEN 1.05
- MACD
- ELVN 0.40
- GDEN -0.17
- Stochastic Oscillator
- ELVN 98.56
- GDEN 47.60
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.